WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 ("AACR 2025") in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title:ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkville for up to a $50 million standby equity purchase agreement, to raise an additional $2 million in debt financing and the sale of up to 500,000 shares of common stock pursuant to forward purchase agreement Financing will support advancement of Abpro's pipeline of its next-generation antibody therapies for cancer, ophthalmology, and infectious diseases WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and l

4 - Abpro Holdings, Inc. (0001893219) (Issuer)

4/A - Abpro Holdings, Inc. (0001893219) (Issuer)

4 - Abpro Holdings, Inc. (0001893219) (Issuer)

3 - Abpro Holdings, Inc. (0001893219) (Issuer)

4 - Abpro Holdings, Inc. (0001893219) (Issuer)

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co